🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

AKUMS DRUGS AND PHARMA L AKUMS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.akums.in
Company Profile ↓
₹696.35
+27.00% 1Y
Mkt Cap₹10,960.13 Cr
P/E30.81
P/B3.16
Div. Yield0.14%
52W High₹701.95
52W Low₹412.10
Book Value₹210.51
EPS (TTM)₹22.60

Company Overview

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 39.1% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 30.8, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.06.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹4,251.31 Cr (+4.4% YoY); net profit ₹255.19 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +4.4%, earnings -24.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.0%, profit CAGR 39.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:6.95%
1 Year:4.43%

Compounded Profit Growth

5 Years:39.08%
1 Year:-24.54%

Stock Price Performance

1 Year:+27.00%
6 Months:+56.59%
3 Months:+27.05%
1 Month:+17.22%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 98% of range
₹412.10 ₹701.95
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)74.10 · Overbought
Price Performance
1M+17.22%
3M+27.05%
6M+56.59%
1Y+27.00%
Valuation vs Sector

P/E of 30.81 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 39.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
30.81
Industry PE
39.97
Forward P/E
22.14
PEG Ratio
-
Book Value
₹210.51
Price to Book
3.16
P/S
2.40
EV/EBITDA
18.17
Dividend Yield
0.14%

Growth (CAGR)

Revenue 5Y
6.95%
Profit 5Y
39.08%
Revenue (YoY)
4.43%
Earnings (YoY)
-24.54%

Profitability & Returns

ROCE
10.82%
ROE
7.70%
ROA
4.68%
Profit Margin
6.00%
Op Margin
8.80%
Gross Margin
40.06%
EPS (Latest Qtr)
₹5.53
EPS (TTM)
₹22.60

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
2.56
Current Ratio
3.25
Debt
₹191.74 Cr
Total Assets
₹5,446.97 Cr
Current Assets
₹3,559.86 Cr
Working Capital
₹2,465.10 Cr

Ownership

Promoter Holding
80.17%
Chg in Prom Hold
4.91%
FII / Inst Holding
13.24%
Chg in FII Hold
-0.14%

Financial Snapshot

Enterprise Value
₹10,960.13 Cr
Total Revenue (TTM)
₹4,251.31 Cr
EBITDA
₹625.27 Cr
Free Cash Flow
₹950.67 Cr
Operating Cash Flow
₹1,181.20 Cr
Shares Outstanding
₹15.74 Cr
Gross Margin
40.06%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AKUMS AKUMS DRUGS AND PHARMA L NSEPHARMA 696.35 30.81 ₹10,960.13 Cr 0.14% 10.82% 7.70% 6.95% 39.08%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 970.00 Cr1,181.00 Cr1,083.00 Cr944.00 Cr1,019.00 Cr--1,055.55 Cr1,024.03 Cr1,017.53 Cr1,159.59 Cr1,157.87 Cr
Cost of Revenue -------639.09 Cr581.92 Cr592.56 Cr678.58 Cr660.46 Cr
Gross Profit -------416.46 Cr442.12 Cr424.97 Cr481.01 Cr497.41 Cr
Operating Expenses 1,095.00 Cr1,029.00 Cr989.00 Cr941.00 Cr891.00 Cr--362.55 Cr350.07 Cr368.36 Cr373.80 Cr385.80 Cr
Operating Income -155.00 Cr122.00 Cr61.00 Cr-31.00 Cr94.00 Cr--53.92 Cr92.05 Cr56.61 Cr107.21 Cr111.60 Cr
EBITDA -125.00 Cr152.00 Cr93.00 Cr3.00 Cr128.00 Cr--119.67 Cr150.83 Cr123.44 Cr162.96 Cr185.23 Cr
Interest Expense 12.00 Cr14.00 Cr12.00 Cr12.00 Cr13.00 Cr--4.54 Cr18.26 Cr19.90 Cr23.74 Cr23.89 Cr
Pretax Income -159.00 Cr87.00 Cr59.00 Cr-33.00 Cr87.00 Cr--75.14 Cr95.65 Cr65.67 Cr99.57 Cr121.22 Cr
Tax Provision -28.62 Cr53.94 Cr-135.11 Cr-6.60 Cr26.10 Cr---74.47 Cr30.96 Cr22.98 Cr31.89 Cr39.87 Cr
Net Income -187.00 Cr33.00 Cr195.00 Cr-39.00 Cr61.00 Cr--147.62 Cr63.48 Cr40.78 Cr66.32 Cr84.61 Cr
Diluted EPS -13.162.2213.54-2.894.08--9.644.152.664.335.53

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,464.00 Cr1,651.00 Cr2,414.00 Cr2,723.00 Cr-3,474.76 Cr4,019.68 Cr4,071.09 Cr4,251.31 Cr
Cost of Revenue -----2,307.47 Cr2,582.22 Cr2,465.74 Cr2,548.21 Cr
Gross Profit -----1,167.29 Cr1,437.46 Cr1,605.36 Cr1,703.10 Cr
Operating Expenses 1,340.00 Cr1,507.00 Cr2,240.00 Cr2,485.00 Cr-975.98 Cr1,077.56 Cr1,294.70 Cr1,329.13 Cr
Operating Income 93.00 Cr106.00 Cr107.00 Cr168.00 Cr-191.31 Cr359.90 Cr310.65 Cr373.97 Cr
EBITDA 124.00 Cr144.00 Cr174.00 Cr238.00 Cr-309.08 Cr130.61 Cr529.11 Cr625.27 Cr
Interest Expense 23.00 Cr22.00 Cr20.00 Cr7.00 Cr-45.97 Cr50.25 Cr30.41 Cr88.62 Cr
Pretax Income 77.00 Cr89.00 Cr114.00 Cr172.00 Cr-150.30 Cr-45.28 Cr345.25 Cr382.10 Cr
Tax Provision 39.27 Cr44.50 Cr70.68 Cr48.16 Cr-52.48 Cr-46.07 Cr1.48 Cr125.70 Cr
Net Income 43.00 Cr61.00 Cr44.00 Cr123.00 Cr-94.86 Cr-4.04 Cr338.18 Cr255.19 Cr
Diluted EPS 366.55523.23335.61943.49-16.046.03-0.2822.60-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,042.00 Cr1,161.00 Cr2,037.00 Cr2,152.00 Cr-3,266.53 Cr3,516.36 Cr4,113.44 Cr5,446.97 Cr
Current Assets -----1,924.16 Cr1,940.88 Cr2,274.61 Cr3,559.86 Cr
Cash & Equivalents -----51.61 Cr111.05 Cr101.19 Cr385.90 Cr
Inventory -----729.79 Cr630.42 Cr680.93 Cr755.71 Cr
Receivables -----845.09 Cr833.81 Cr770.30 Cr796.56 Cr
Total Liabilities -----2,543.15 Cr2,795.88 Cr1,049.83 Cr2,115.84 Cr
Current Liabilities -----1,265.57 Cr1,210.55 Cr893.75 Cr1,094.76 Cr
Long Term Debt ----13.33 Cr115.50 Cr78.30 Cr0-
Total Debt 255.00 Cr213.00 Cr175.00 Cr130.00 Cr-619.09 Cr565.23 Cr88.21 Cr191.74 Cr
Total Equity 494.00 Cr629.00 Cr722.00 Cr885.00 Cr-717.19 Cr709.50 Cr3,047.01 Cr3,313.35 Cr
Shares Outstanding -----15.31 Cr15.31 Cr15.74 Cr15.74 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 72.00 Cr89.00 Cr28.00 Cr131.00 Cr-176.63 Cr498.26 Cr465.20 Cr1,181.20 Cr
Investing Cash Flow -150.00 Cr-123.00 Cr-190.00 Cr-109.00 Cr--304.70 Cr-330.42 Cr-547.84 Cr-930.27 Cr
Financing Cash Flow 66.00 Cr37.00 Cr233.00 Cr-91.00 Cr-124.54 Cr-108.02 Cr72.79 Cr33.88 Cr
Capital Expenditure -150.00 Cr-123.00 Cr-62.00 Cr-82.00 Cr--328.79 Cr-311.41 Cr-272.31 Cr-230.53 Cr
Free Cash Flow -78.00 Cr-34.00 Cr-34.00 Cr49.00 Cr--152.16 Cr186.85 Cr192.88 Cr950.67 Cr
Net Change in Cash -11.00 Cr4.00 Cr71.00 Cr-70.00 Cr--3.53 Cr59.82 Cr-9.86 Cr284.81 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -----33.6%35.8%39.4%40.1%
Operating Margin % 6.4%6.4%4.4%6.2%-5.5%9.0%7.6%8.8%
Net Margin % 2.9%3.7%1.8%4.5%-2.7%-0.1%8.3%6.0%
ROE % 8.7%9.7%6.1%13.9%-13.2%-0.6%11.1%7.7%
ROCE % -----9.6%15.6%9.6%8.6%

Shareholding Pattern

Insiders
80.17%
Institutions
13.24%
Public Float
66.77%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AKUMS

Yahoo Finance Wed, 20 May 2026

Akums Drugs and Pharmaceuticals Ltd (BOM:544222) Q4 2026 Earnings Call Highlights: Strong ...

Despite challenges in certain segments, Akums Drugs and Pharmaceuticals Ltd (BOM:544222) reports robust financial performance and outlines plans for international market expansion.

Yahoo Finance Mon, 23 Feb 2026

Akums Strengthens European and UK Presence -- India's Largest CDMO Expands Global Footprint

Akums Drugs & Pharmaceuticals Ltd., India's largest CDMO, has secured European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities located in India, reinforcing its growing presence in regulated …

Yahoo Finance Wed, 18 Feb 2026

Akums Drugs and Pharmaceuticals Ltd (BOM:544222) Q3 2026 Earnings Call Highlights: Strong CDMO ...

Akums Drugs and Pharmaceuticals Ltd (BOM:544222) reports robust growth in CDMO and international segments, while addressing challenges in API pricing and trade generics.

Yahoo Finance Fri, 14 Nov 2025

Akums Drugs and Pharmaceuticals Ltd (BOM:544222) Q2 2026 Earnings Call Highlights: Strategic ...

Despite a challenging quarter with declining revenues and margins, Akums Drugs and Pharmaceuticals Ltd (BOM:544222) focuses on strategic growth initiatives and European market penetration.

Yahoo Finance hu, 21 Aug 2025

Akums Receives ANVISA GMP Certification for Sterile Manufacturing Plant, Expands Global Sterile Manufacturing Footprint

Delhi, India--(Newsfile Corp. - August 21, 2025) - Akums Drugs & Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), proudly announces that its Sterile Manufacturing Plant has been granted the p…

AKUMS — Frequently Asked Questions

What is the current share price of AKUMS DRUGS AND PHARMA L (AKUMS)?

As of 2026-07-15 09:52 IST, AKUMS DRUGS AND PHARMA L (AKUMS) trades at ₹696.35 on NSE. Its 52-week range is ₹412.10 to ₹701.95.

What is the market capitalisation of AKUMS?

AKUMS DRUGS AND PHARMA L (AKUMS) has a market capitalisation of ₹10,960.13 Cr on NSE.

What is the P/E ratio of AKUMS?

AKUMS trades at a trailing price-to-earnings (P/E) ratio of 30.81. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.16.

Does AKUMS pay a dividend?

AKUMS DRUGS AND PHARMA L (AKUMS) currently offers a dividend yield of 0.14%.

What is the return on equity (ROE) of AKUMS?

AKUMS has a return on equity (ROE) of 7.70%. Its return on capital employed (ROCE) is 10.82%.

Is AKUMS a good stock to buy?

This page provides a data-driven analysis of AKUMS DRUGS AND PHARMA L (AKUMS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space